Scarica l'app Stockscreener
2.33
4.51%
-0.11
Dopo l'orario di chiusura:
2.33
Precedente Chiudi:
$2.44
Aprire:
$2.42
Volume 24 ore:
751.11K
Relative Volume:
0.27
Capitalizzazione di mercato:
$279.18M
Reddito:
$6.65M
Utile/perdita netta:
$-136.32M
Rapporto P/E:
-2.0301
EPS:
-1.1477
Flusso di cassa netto:
$-112.04M
1 W Prestazione:
-3.72%
1M Prestazione:
-15.58%
6M Prestazione:
+80.62%
1 anno Prestazione:
+133.00%
Intervallo 1D:
$2.28
$2.45
Intervallo di 1 settimana:
$2.28
$2.55
Portata 52W:
$0.9401
$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.33 | 292.36M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-19 | Ripresa | Jefferies | Buy |
| 2025-10-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Canada
Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative
FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Sixteen lupus patients had no severe immune reactions in early cell-therapy data - Stock Titan
Fate Therapeutics Market Sentiment - Benzinga España
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Fate Therapeutics stock holds steady as investors watch cash runway and pipeline - ad-hoc-news.de
FATE Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusPost-Earnings Drift - vinanet.vn
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference - GlobeNewswire
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics stock stabilizes after autoimmune CAR-T safety shock - ad-hoc-news.de
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE) - Seeking Alpha
574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
symbol__ Stock Quote Price and Forecast - CNN
Fate Therapeutics (FATE) Gains 1.98% to $2.57 as Stock Holds Above Key SupportStock News - dars.gov.et
Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics (FATE) Rises 1.98% to $2.57 as it Approaches Key ResistanceAdvance Decline Line - vinanet.vn
Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Australia
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis - BioPharm International
Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Therapeutics doses first patient in FT819 lupus trial - Investing.com
Fate Therapeutics doses first patient in FT819 lupus trial By Investing.com - Investing.com Nigeria
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis - TradingView
Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis - Quiver Quantitative
Fate Therapeutics' First FT819 Patient Went Home Same Day - Stock Titan
FATE THERAPEUTICSPATIENTS TO RECEIVE SINGLE 900 MLN-CELL DOSE OF FT819; PRIMARY ENDPOINT AT WEEK 26 - webull.com
FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5 - Bitget
Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo! Finance Canada
Fate Therapeutics Reports Q2 2026 10-Q Filing Highlighting iPSC Pipeline and Key Risks - Kalkine Media
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Form 8K Fate Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia
Fate Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises - TradingView
Fate Therapeutics Reports $30.2 Million Second-Quarter Net Loss - Quiver Quantitative
Fate Therapeutics reports Q2 2026: $2.1M revenue, $30.2M net loss, cash $153.8M - TradingView
Fate Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - tradingview.com
Fate Therapeutics (FATE) Short Interest & Short Float | Updated Aug 2026 $FATE - MarketBeat
FATE Stock Price and Chart — NASDAQ:FATE - TradingView
Renaissance Technologies LLC Increases Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):